<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Contrast echocardiography: Contrast agents, safety, and imaging technique
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Contrast echocardiography: Contrast agents, safety, and imaging technique
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Contrast echocardiography: Contrast agents, safety, and imaging technique
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Hanna Ahmed, MD, MPH, FACC
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Warren J Manning, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Susan B Yeon, MD, JD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 06, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Contrast echocardiography is a technique for improving echocardiographic resolution and providing real-time assessment of intracardiac blood flow. Agitated
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         contrast provides contrast in the right heart and enables detection of right to left shunts. Opacification of the left ventricular (LV) cavity by contrast agents developed to traverse the pulmonary vasculature permits improved endocardial border detection [
         <a href="#rid1">
          1
         </a>
         ]. A 2018 update to the American Society of Echocardiography guidelines proposed ultrasound enhancing agents (UEAs) as an alternative name for echocardiographic contrast agents to help patients and providers distinguish these agents from other iodinated contrast agents and gadolinium [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         The only US Food and Drug Administration (FDA)-approved indication for the use of UEAs in cardiac imaging is for LV opacification via an intravenous injection. There are many other off label uses of UEAs, including use during stress echocardiography, enhancement of Doppler signal, as well as assessing myocardial perfusion [
         <a href="#rid3">
          3
         </a>
         ] and viability [
         <a href="#rid4">
          4
         </a>
         ]. Another off label use is intracoronary injection during alcohol septal ablation for hypertrophic cardiomyopathy patients [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         The development and safety of microbubbles for echocardiographic contrast and the optimization of the echocardiographic settings for visualizing contrast will be reviewed here. The current and potential clinical applications of contrast echocardiography are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5313.html" rel="external">
          "Contrast echocardiography: Clinical applications"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          MICROBUBBLE CONTRAST AGENTS
         </span>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Mechanism of contrast
         </span>
         <span class="headingEndMark">
          —
         </span>
         As sound travels from one medium to another, the change in density (known as acoustic impedance) at the interface causes the reflection of sound waves [
         <a href="#rid6">
          6
         </a>
         ]. The greater the difference in the media densities, the more echogenic the interface. Gas is an excellent contrast agent since it is 100,000 times less dense than blood.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Agitated saline contrast
         </span>
         <span class="headingEndMark">
          —
         </span>
         Agitated
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         solution administered via intravenous injection provides air microbubble contrast in the right heart. The air microbubbles are short-lived and diffuse into the lungs when traversing the pulmonary circulation. Therefore the microbubbles enter the left heart only in the presence of a right to left intracardiac or extracardiac (pulmonary arteriovenous) shunt. Saline microbubbles are therefore helpful in examining the right heart and identifying shunts. (See
         <a class="medical medical_review" href="/z/d/html/5313.html" rel="external">
          "Contrast echocardiography: Clinical applications", section on 'Agitated saline contrast'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1420.html" rel="external">
          "Patent foramen ovale", section on 'Ultrasound techniques'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Contrast agents for LV opacification
         </span>
         <span class="headingEndMark">
          —
         </span>
         To allow left heart evaluation, an ideal contrast microbubble must be small and durable enough to traverse the pulmonary circulation to pass into the left heart from an intravenous injection. Improvements in contrast agents have resulted from the exploitation of knowledge concerning both the mechanisms of echogenicity and the impediments to transpulmonary passage.
        </p>
        <p>
         Larger microbubble size enhances durability, which is proportional to the square of the bubble radius [
         <a href="#rid7">
          7
         </a>
         ]. However, a small bubble size (diameter ≤10 micrometers) is required for successful transpulmonary passage [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         Contrast agents must meet the following requirements: safe, metabolically inert, long lasting, strong reflector of ultrasound, and small enough to pass through capillaries [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         Surrounding the gas bubble in a durable shell enables adequate durability while keeping bubble size small enough to traverse the pulmonary circulation. A number of microbubble capsules have been investigated but produced bubbles that were too large (eg,
         <a class="drug drug_general" data-topicid="8982" href="/z/d/drug information/8982.html" rel="external">
          indocyanine green
         </a>
         dye) or too short-lived (eg, polysaccharide or gelatin-encapsulated air) to opacify the left heart [
         <a href="#rid10">
          10
         </a>
         ]. Further stabilization of the microbubble was achieved through the use of a 5 percent human
         <a class="drug drug_general" data-topicid="9376" href="/z/d/drug information/9376.html" rel="external">
          albumin solution
         </a>
         , which forms a thin shell of denatured albumin when sonicated [
         <a href="#rid11">
          11
         </a>
         ]; this led to the development of Albunex as the first FDA-approved myocardial contrast agent. However, the clinical utility of Albunex was limited because microbubble air loss results in large decreases in echogenicity, although it causes only slight decreases in bubble diameter [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         Further improvements in microbubble capsules have been incorporated into second-generation agents. Gas diffusion was decreased via the use of inert gases (eg, perfluorocarbons) to form the microbubbles. Improved bubble surface stability was attained through use of innovative colloidal suspensions or emulsions.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h3">
          Second-generation contrast agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are three agents that are commercially available worldwide for cardiac ultrasound imaging [
         <a href="#rid2">
          2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10335" href="/z/d/drug information/10335.html" rel="external">
          Perflutren protein type A
         </a>
         <strong>
          (Optison)
         </strong>
         – A human albumin-based shell enclosing octafluoropropane gas (perflutren) [
         <a href="#rid13">
          13,14
         </a>
         ]. This agent is FDA approved and is also available in Canada.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10142" href="/z/d/drug information/10142.html" rel="external">
          Perflutren lipid microspheres
         </a>
         <strong>
          (Definity)
         </strong>
         – A phospholipid shell enclosing octafluoropropane gas (perflutren) [
         <a href="#rid12">
          12,15
         </a>
         ]. This agent is FDA approved and is also available in Europe (known as Lumity), Canada, Australia, and in parts of Asia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sulfur hexafluoride lipid microsphere (Lumason)
         </strong>
         – A phospholipid shell enclosing sulfur hexafluoride gas. This agent is FDA approved and is available in Canada, Europe, and some Latin American and Asian countries.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          SAFETY
         </span>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Agitated saline safety
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although reports of complications are scant, case reports suggest that agitated
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         injection can rarely cause ischemic complications such as stroke or transient ischemic attack. One report compiled five cases of cerebral ischemic events (three ischemic strokes and two transient ischemic attacks) occurring immediately or within five minutes of agitated saline contrast study demonstrating a right-to-left shunt [
         <a href="#rid16">
          16
         </a>
         ]. Available data are not sufficient to estimate the incidence of such events, although such complications appear to be rare.
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Second-generation contrast safety
         </span>
         <span class="headingEndMark">
          —
         </span>
         The FDA approved
         <a class="drug drug_general" data-topicid="10335" href="/z/d/drug information/10335.html" rel="external">
          perflutren protein type A
         </a>
         (Optison) and
         <a class="drug drug_general" data-topicid="10142" href="/z/d/drug information/10142.html" rel="external">
          perflutren lipid microspheres
         </a>
         (Definity) for cardiac indications after clinical trial experience, including detailed safety evaluations [
         <a href="#rid14">
          14,15
         </a>
         ]. Sulfur hexafluoride lipid microsphere (Lumason) was approved by the FDA for cardiac imaging in adults in 2014 and, subsequently, was approved for use in cardiac imaging in pediatric patients in 2019.
        </p>
        <p>
         Initial postmarketing approval surveillance over five years and in greater than one million patients demonstrated no medically significant risks other than rare allergic events at a rate of approximately 1 per 10,000 [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
         The rare severe allergic reactions are thought to be a variant of the type I hypersensitivity reaction known as Complement Activation Related Pseudo Allergy (CARPA). These are not immunoglobulin E (IgE)-mediated. There is a higher rate of reaction in women and atopic individuals. CARPA reactions may be mild to moderate (eg, urticaria, pruritus, tingling, sneezing) or severe (eg, wheezing, angioedema, cyanosis, anaphylactic shock) [
         <a href="#rid17">
          17,18
         </a>
         ]. All personnel utilizing these agents should be trained in recognizing and treating these reactions.
        </p>
        <p>
         Central nervous system reactions have also rarely been reported and may or may not be associated with hypersensitivity reactions. Reported adverse events are generally infrequent and mild and may include headache, weakness, fatigue, palpitations, nausea, dizziness, dry mouth, altered sense of smell or taste, dyspnea, urticaria, pruritus, back pain, chest pain, or rash.
        </p>
        <p>
         Definity, Optison, and Lumason are not recommended for use at mechanical indices greater than 0.8. A high ultrasound mechanical index value may cause microsphere cavitation or rupture and lead to ventricular arrhythmias. In addition, end-systolic triggering with high mechanical indices has been reported to cause ventricular arrhythmias [
         <a href="#rid19">
          19-21
         </a>
         ].
        </p>
        <p>
         In 2011, the FDA removed the previously mandated 30-minute monitoring period after contrast administration in patients with pulmonary hypertension or unstable cardiopulmonary conditions. The revised labeling of all contrast agents now lists an acknowledgment that serious cardiopulmonary reactions after contrast administration are rare and typically occur within 30 minutes. All personnel utilizing these agents should be trained in recognizing these reactions, and resuscitative equipment should be readily available for use by trained individuals.
        </p>
        <p>
         In late 2016 and early 2017, the FDA removed the contraindication for administration of
         <a class="drug drug_general" data-topicid="10335" href="/z/d/drug information/10335.html" rel="external">
          perflutren protein type A
         </a>
         (Optison), sulfur hexafluoride lipid microsphere (Lumason), and
         <a class="drug drug_general" data-topicid="10142" href="/z/d/drug information/10142.html" rel="external">
          perflutren lipid microspheres
         </a>
         (Definity) in patients with intracardiac shunts. This was based on a number of studies that demonstrated the safety of these agents in patients with known shunts [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         In late 2021, the FDA removed the contraindication for hypersensitivity to blood and blood products from the labeling for Optison [
         <a href="#rid20">
          20,23
         </a>
         ].
        </p>
        <p>
         In 2021, MedWatch, the FDA's product safety reporting system, announced that there were 11 cases of anaphylaxis, including two deaths, in patients with a known polyethylene glycol (PEG) hypersensitivity who had received a lipid-based UEA. This led to updated labeling of Definity and Lumason to list PEG allergy or hypersensitivity as a contraindication to the administration of their agents in those patients who have a known allergy or hypersensitivity to PEG, also known as macrogol or polyoxyethylene. Many products contain PEG, such as some laxatives, bowel preparations used prior to colonoscopy, cosmetics, mRNA vaccines, and other household products. The American Society of Echocardiography (ASE) recently published an expert consensus statement acknowledging this issue, and recommended that sonographers inquire about PEG allergy prior to the administration of lipid-based UEAs [
         <a href="#rid24">
          24
         </a>
         ]. The overall incidence of adverse reactions (including PEG hypersensitivity) to UEAs is low (1:10,000), and no additional changes to lab protocols were recommended.
        </p>
        <p>
         Contrast agents can be used in LV assist devices (LVADs) [
         <a href="#rid25">
          25
         </a>
         ] and extracorporeal membrane oxygenator (ECMO), though care must be taken to avoid ECMO circuit shutdown due to bubble sensing safety systems [
         <a href="#rid26">
          26,27
         </a>
         ].
        </p>
        <p>
         The current contraindications to the use of UEAs include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For
         <a class="drug drug_general" data-topicid="10142" href="/z/d/drug information/10142.html" rel="external">
          perflutren lipid microspheres
         </a>
         (Definity), known or suspected hypersensitivity to perflutren or PEG.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For
         <a class="drug drug_general" data-topicid="10335" href="/z/d/drug information/10335.html" rel="external">
          perflutren protein type A
         </a>
         (Optison), known or suspected hypersensitivity to perflutren, blood, blood products, or albumin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For sulfur hexafluoride lipid microsphere (Lumason), known hypersensitivity to sulfur hexafluoride, the inactive components of the contrast agent, or PEG.
        </p>
        <p>
        </p>
        <p>
         Limited data suggest that second-generation contrast agents also appear safe for off-label use in children and adolescents [
         <a href="#rid28">
          28,29
         </a>
         ]. In a single-center retrospective review of 113 patients between ages 5 and 21 years (mean age 17.8 years) who received
         <a class="drug drug_general" data-topicid="10142" href="/z/d/drug information/10142.html" rel="external">
          perflutren lipid microspheres
         </a>
         (Definity) between 2005 and 2014, 13 patients (12 percent) reported a variety of symptoms (eg, chest pain, fatigue, back/neck pain, headache, dizziness, or shortness of breath) lasting less than 60 seconds during contrast administration, and none of the 113 patients were found to have had an adverse event within 24 hours of perflutren lipid microsphere (Definity) administration [
         <a href="#rid28">
          28
         </a>
         ]. Another study included 20 patients (ages 9 to 18 years) who underwent transthoracic echocardiography with
         <a class="drug drug_general" data-topicid="10335" href="/z/d/drug information/10335.html" rel="external">
          perflutren protein type A
         </a>
         (Optison) echocontrast. There were no adverse hemodynamic effects, changes in taste, or flushing episodes. Three patients experienced transient headaches [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
         Sulfur hexafluoride lipid microsphere (Lumason) was initially FDA approved for noncardiac imaging in pediatric patients (eg, liver imaging and evaluation of vesicoureteral reflux). The FDA has also approved the use of sulfur hexafluoride lipid microsphere (Lumason) for cardiac imaging in pediatric patients using a weight-based dose [
         <a href="#rid30">
          30
         </a>
         ]. This is based on a study of 12 pediatric patients (ages 9 to 17 years) with suspected cardiac disease and suboptimal noncontrast echocardiography who received Lumason in one prospective multicenter clinical trial, as well as extrapolation from prior data on pediatric use in liver imaging and adult use in cardiac imaging. No major adverse effects were reported in the 12 pediatric patients who received Lumason in the cardiac study. Of note, patients with intracardiac shunts were excluded from this trial, as this was a contraindication at the time the study commenced.
        </p>
        <p>
         There are no studies on the safety of UEAs in children under the age of five years [
         <a href="#rid2">
          2
         </a>
         ]. There are no data on the safety of contrast agents in pregnancy or lactation.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          OPTIMAL ECHOCARDIOGRAPHIC SETTINGS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Contrast agent durability is dependent upon both bubble composition and ultrasonic characteristics. Alterations in the echocardiographic settings can therefore optimize both microbubble durability and contrast intensity. Guidelines for equipment setup and contrast agent administration are included in the 2008 American Society of Echocardiography consensus statement on contrast agents in echocardiography [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Harmonic detection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Second harmonic detection systems improve the signal-to-noise ratio of contrast images [
         <a href="#rid31">
          31,32
         </a>
         ].
        </p>
        <p>
         Microbubbles resonate (shake) with exposure to ultrasound energy at frequencies that are multiples of the ultrasound frequency emitted from the transducer. This results in the emission of fundamentals (same frequency) and harmonics (multiples) of the frequency to which they are exposed [
         <a href="#rid33">
          33
         </a>
         ]. By setting the imaging frequency of the echo system to a harmonic of the emitted frequency, the system "filters" out all returning fundamental frequencies from the myocardium and enhances the microbubble signal.
        </p>
        <p>
         The contrast intensity improves two to three times using second harmonics [
         <a href="#rid34">
          34
         </a>
         ]. Other advantages to harmonic imaging include decreased artifact and shadowing, as well as enhanced contrast detection in areas of low microbubble concentration [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
         Harmonic imaging also improves endocardial tracking even without echocardiographic contrast (see
         <a class="medical medical_review" href="/z/d/html/5316.html" rel="external">
          "Echocardiography essentials: Physics and instrumentation", section on 'Second harmonic imaging'
         </a>
         ). However, the ejection fraction obtained by harmonic imaging along with contrast echocardiography provides the closest correlation with the radionuclide ejection fraction [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Intermittent or transient imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         When a sound wave interacts with a microbubble, some of the energy is reflected, but a portion actively destroys the microbubbles. As a result, continuous ultrasound imaging results in depletion of the microbubble population, giving a suboptimal signal-to-noise ratio [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         Increased microbubble durability may be accomplished with intermittent or transient response imaging [
         <a href="#rid37">
          37
         </a>
         ]. Ultrasound that is emitted only once per cardiac cycle, or as infrequently as every 5 to 10 beats, improves microbubble contrast intensity inversely with bubble transit velocity [
         <a href="#rid38">
          38
         </a>
         ]. Controversy exists as to which part of the cardiac cycle should be imaged; however, either systolic or diastolic imaging appears to improve the contrast effect [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Low mechanical index imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Another technique to decrease the destruction of microbubbles is low mechanical index imaging. If a very low acoustic power is transmitted, fewer bubbles will be destroyed even with continuous imaging. Commercial echocardiographic machines now have this "real-time" contrast imaging and studies assessing its utility are ongoing.
        </p>
        <p>
         Images may also be enhanced using Doppler technology with power-Doppler imaging [
         <a href="#rid39">
          39,40
         </a>
         ] and/or ultrasound pulse inversion technology [
         <a href="#rid2">
          2,41
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Mode of contrast injection
         </span>
         <span class="headingEndMark">
          —
         </span>
         The mode of contrast injection can affect image quality. Steady state infusions offer an advantage over single or multiple bolus injections of agents by allowing titration to an optimal and uniform image and extending the duration of LV opacification, allowing for time to assess multiple anatomic views [
         <a href="#rid42">
          42,43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1035271852">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Contrast echocardiography is a technique for improving echocardiographic resolution and providing real-time assessment of intracardiac blood flow using ultrasound enhancing agents (UEAs). (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Second-generation contrast agents surrounding the gas bubble in a durable shell enable adequate durability while keeping bubble size small enough to traverse the pulmonary circulation and enhance the LV cavity, improving endocardial border delineation. (See
         <a class="local">
          'Microbubble contrast agents'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Several studies have demonstrated the safety of these second-generation contrast agents. (See
         <a class="local">
          'Safety'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Contraindications to the use of UEAs include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For
         <a class="drug drug_general" data-topicid="10142" href="/z/d/drug information/10142.html" rel="external">
          perflutren lipid microspheres
         </a>
         (Definity), known or suspected hypersensitivity to perflutren or polyethylene glycol (PEG).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For
         <a class="drug drug_general" data-topicid="10335" href="/z/d/drug information/10335.html" rel="external">
          perflutren protein type A
         </a>
         (Optison), known or suspected hypersensitivity to perflutren or albumin.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For sulfur hexafluoride lipid microsphere (Lumason), known hypersensitivity to sulfur hexafluoride, the inactive components of the contrast agent, or PEG.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Contrast agents require different echocardiography machine settings to enhance their utility. (See
         <a class="local">
          'Optimal echocardiographic settings'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3921348128">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Neil J Weissman, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Mulvagh SL, Rakowski H, Vannan MA, et al. American Society of Echocardiography Consensus Statement on the Clinical Applications of Ultrasonic Contrast Agents in Echocardiography. J Am Soc Echocardiogr 2008; 21:1179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Porter TR, Mulvagh SL, Abdelmoneim SS, et al. Clinical Applications of Ultrasonic Enhancing Agents in Echocardiography: 2018 American Society of Echocardiography Guidelines Update. J Am Soc Echocardiogr 2018; 31:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Porter TR, Li S, Kricsfeld D, Armbruster RW. Detection of myocardial perfusion in multiple echocardiographic windows with one intravenous injection of microbubbles using transient response second harmonic imaging. J Am Coll Cardiol 1997; 29:791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rovai D, Zanchi M, Lombardi M, et al. Residual myocardial perfusion in reversibly damaged myocardium by dipyridamole contrast echocardiography. Eur Heart J 1996; 17:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagueh SF, Bierig SM, Budoff MJ, et al. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: Endorsed by the American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomography. J Am Soc Echocardiogr 2011; 24:473.
          </a>
         </li>
         <li class="breakAll">
          Feigenbaum H. Instrumentation. In: Echocardiography, Feigenbaum H (Ed), Lea and Febiger, Philadelphia 1981. p.3.
         </li>
         <li class="breakAll">
          Berwing K, Schlepper M, Bahavar H, Buchwald A. Significance and selection of contrast solution for myocardial contrast echocardiography. In: Myocardial Contrast Two-Dimensional Echocardiography, Meerbaum S, Meltzer R (Eds), Kluwer Academic Publishers, Boston 1989. p.63.
         </li>
         <li class="breakAll">
          Meerbaum S. Development and validation of MC-2DE methodology. In: Myocardial Contrast Two-Dimensional Echocardiography, Meerbaum S, Meltzer R (Eds), Kluwer Academic Publishers, Boston 1989. p.24.
         </li>
         <li class="breakAll">
          Edelman S. Understanding Ultrasound Physics, 4th ed, E.S.P. Ultrasound, Woodlands, TX 2012.
         </li>
         <li class="breakAll">
          Meerbaum S. Introduction and general background. In: Myocardial Contrast Two-Dimensional Echocardiography, Meerbaum S, Meltzer R (Eds), Kluwer Academic Publishers, Boston 1989. p.3.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feinstein SB, Cheirif J, Ten Cate FJ, et al. Safety and efficacy of a new transpulmonary ultrasound contrast agent: initial multicenter clinical results. J Am Coll Cardiol 1990; 16:316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaul S. Myocardial contrast echocardiography: 15 years of research and development. Circulation 1997; 96:3745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meza M, Greener Y, Hunt R, et al. Myocardial contrast echocardiography: reliable, safe, and efficacious myocardial perfusion assessment after intravenous injections of a new echocardiographic contrast agent. Am Heart J 1996; 132:871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen JL, Cheirif J, Segar DS, et al. Improved left ventricular endocardial border delineation and opacification with OPTISON (FS069), a new echocardiographic contrast agent. Results of a phase III Multicenter Trial. J Am Coll Cardiol 1998; 32:746.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kitzman DW, Goldman ME, Gillam LD, et al. Efficacy and safety of the novel ultrasound contrast agent perflutren (definity) in patients with suboptimal baseline left ventricular echocardiographic images. Am J Cardiol 2000; 86:669.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romero JR, Frey JL, Schwamm LH, et al. Cerebral ischemic events associated with 'bubble study' for identification of right to left shunts. Stroke 2009; 40:2343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herzog CA. Incidence of adverse events associated with use of perflutren contrast agents for echocardiography. JAMA 2008; 299:2023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 2005; 216:106.
          </a>
         </li>
         <li class="breakAll">
          Definity (perflutren) injection label. United States prescribing information. Revised August, 2011. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021064s011lbl.pdf (Accessed on September 07, 2023).
         </li>
         <li class="breakAll">
          Optison (perflutren protein-type A microspheres injectable suspension, USP). United States prescribing information. Revised May, 2012. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020899s015lbl.pdf (Accessed on September 07, 2023).
         </li>
         <li class="breakAll">
          Lumason (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use. United States prescribing information. Revised April, 2021. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/203684s009lbl.pdf (Accessed on September 07, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muskula PR, Main ML. Safety With Echocardiographic Contrast Agents. Circ Cardiovasc Imaging 2017; 10.
          </a>
         </li>
         <li class="breakAll">
          FDA approves change in contraindications in prescribing information for Optison from GE. AppliedRadiology. https://appliedradiology.com/articles/fda-approves-change-in-contraindications-in-prescribing-information-for-optison-from-ge (Accessed on September 07, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindner JR, Belcik T, Main ML, et al. Expert Consensus Statement from the American Society of Echocardiography on Hypersensitivity Reactions to Ultrasound Enhancing Agents in Patients with Allergy to Polyethylene Glycol. J Am Soc Echocardiogr 2021; 34:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fine NM, Abdelmoneim SS, Dichak A, et al. Safety and feasibility of contrast echocardiography for LVAD evaluation. JACC Cardiovasc Imaging 2014; 7:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bennett CE, Tweet MS, Michelena HI, et al. Safety and Feasibility of Contrast Echocardiography for ECMO Evaluation. JACC Cardiovasc Imaging 2017; 10:603.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grecu L, Fishman MA. Beware of life-threatening activation of air bubble detector during contrast echocardiography in patients on venoarterial extracorporeal membrane oxygenator support. J Am Soc Echocardiogr 2014; 27:1130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kutty S, Xiao Y, Olson J, et al. Safety and Efficacy of Cardiac Ultrasound Contrast in Children and Adolescents for Resting and Stress Echocardiography. J Am Soc Echocardiogr 2016; 29:655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McMahon CJ, Ayres NA, Bezold LI, et al. Safety and efficacy of intravenous contrast imaging in pediatric echocardiography. Pediatr Cardiol 2005; 26:413.
          </a>
         </li>
         <li class="breakAll">
          https://clinicaltrials.gov/ct2/show/NCT02282163 (Accessed on July 18, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindner JR, Firschke C, Wei K, et al. Myocardial perfusion characteristics and hemodynamic profile of MRX-115, a venous echocardiographic contrast agent, during acute myocardial infarction. J Am Soc Echocardiogr 1998; 11:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindner JR, Dent JM, Moos SP, et al. Enhancement of left ventricular cavity opacification by harmonic imaging after venous injection of Albunex. Am J Cardiol 1997; 79:1657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaul S. New developments in ultrasound systems for contrast echocardiography. Clin Cardiol 1997; 20:I27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Colon PJ 3rd, Richards DR, Moreno CA, et al. Benefits of reducing the cardiac cycle-triggering frequency of ultrasound imaging to increase myocardial opacification with FSO69 during fundamental and second harmonic imaging. J Am Soc Echocardiogr 1997; 10:602.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nahar T, Croft L, Shapiro R, et al. Comparison of four echocardiographic techniques for measuring left ventricular ejection fraction. Am J Cardiol 2000; 86:1358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wei K, Skyba DM, Firschke C, et al. Interactions between microbubbles and ultrasound: in vitro and in vivo observations. J Am Coll Cardiol 1997; 29:1081.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Firschke C, Lindner JR, Wei K, et al. Myocardial perfusion imaging in the setting of coronary artery stenosis and acute myocardial infarction using venous injection of a second-generation echocardiographic contrast agent. Circulation 1997; 96:959.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ohmori K, Cotter B, Kwan OL, et al. Relation of contrast echo intensity and flow velocity to the amplification of contrast opacification produced by intermittent ultrasound transmission. Am Heart J 1997; 134:1066.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sutherland GR, Stewart MJ, Groundstroem KW, et al. Color Doppler myocardial imaging: a new technique for the assessment of myocardial function. J Am Soc Echocardiogr 1994; 7:441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tuchnitz A, von Bibra H, Sutherland GR, et al. Doppler energy: a new acquisition technique for the transthoracic detection of myocardial perfusion defects with the use of a venous contrast agent. J Am Soc Echocardiogr 1997; 10:881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Venkatraman S, Rao NA. Combining pulse compression and adaptive drive signal design to inverse filter the transducer system response and improve resolution in medical ultrasound. Med Biol Eng Comput 1996; 34:318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albrecht T, Urbank A, Mahler M, et al. Prolongation and optimization of Doppler enhancement with a microbubble US contrast agent by using continuous infusion: preliminary experience. Radiology 1998; 207:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weissman NJ, Cohen MC, Hack TC, et al. Infusion versus bolus contrast echocardiography: a multicenter, open-label, crossover trial. Am Heart J 2000; 139:399.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5301 Version 20.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18992671" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : American Society of Echocardiography Consensus Statement on the Clinical Applications of Ultrasonic Contrast Agents in Echocardiography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29502588" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Clinical Applications of Ultrasonic Enhancing Agents in Echocardiography: 2018 American Society of Echocardiography Guidelines Update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9091526" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Detection of myocardial perfusion in multiple echocardiographic windows with one intravenous injection of microbubbles using transient response second harmonic imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8732385" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Residual myocardial perfusion in reversibly damaged myocardium by dipyridamole contrast echocardiography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21514501" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: Endorsed by the American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21514501" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: Endorsed by the American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21514501" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: Endorsed by the American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21514501" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: Endorsed by the American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21514501" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: Endorsed by the American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21514501" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: Endorsed by the American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2197312" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Safety and efficacy of a new transpulmonary ultrasound contrast agent: initial multicenter clinical results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9396479" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Myocardial contrast echocardiography: 15 years of research and development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8831379" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Myocardial contrast echocardiography: reliable, safe, and efficacious myocardial perfusion assessment after intravenous injections of a new echocardiographic contrast agent.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9741522" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Improved left ventricular endocardial border delineation and opacification with OPTISON (FS069), a new echocardiographic contrast agent. Results of a phase III Multicenter Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10980221" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Efficacy and safety of the novel ultrasound contrast agent perflutren (definity) in patients with suboptimal baseline left ventricular echocardiographic images.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19498192" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Cerebral ischemic events associated with 'bubble study' for identification of right to left shunts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18460662" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Incidence of adverse events associated with use of perflutren contrast agents for echocardiography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16140450" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16140450" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16140450" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16140450" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28377467" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Safety With Echocardiographic Contrast Agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28377467" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Safety With Echocardiographic Contrast Agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33971277" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Expert Consensus Statement from the American Society of Echocardiography on Hypersensitivity Reactions to Ultrasound Enhancing Agents in Patients with Allergy to Polyethylene Glycol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24742894" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Safety and feasibility of contrast echocardiography for LVAD evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27424246" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Safety and Feasibility of Contrast Echocardiography for ECMO Evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25087080" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Beware of life-threatening activation of air bubble detector during contrast echocardiography in patients on venoarterial extracorporeal membrane oxygenator support.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27049664" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Safety and Efficacy of Cardiac Ultrasound Contrast in Children and Adolescents for Resting and Stress Echocardiography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16374692" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Safety and efficacy of intravenous contrast imaging in pediatric echocardiography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16374692" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Safety and efficacy of intravenous contrast imaging in pediatric echocardiography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9487468" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Myocardial perfusion characteristics and hemodynamic profile of MRX-115, a venous echocardiographic contrast agent, during acute myocardial infarction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9202358" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Enhancement of left ventricular cavity opacification by harmonic imaging after venous injection of Albunex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9383599" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : New developments in ultrasound systems for contrast echocardiography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9282349" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Benefits of reducing the cardiac cycle-triggering frequency of ultrasound imaging to increase myocardial opacification with FSO69 during fundamental and second harmonic imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11113413" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Comparison of four echocardiographic techniques for measuring left ventricular ejection fraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9120163" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Interactions between microbubbles and ultrasound: in vitro and in vivo observations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9264507" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Myocardial perfusion imaging in the setting of coronary artery stenosis and acute myocardial infarction using venous injection of a second-generation echocardiographic contrast agent.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9424067" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Relation of contrast echo intensity and flow velocity to the amplification of contrast opacification produced by intermittent ultrasound transmission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7986541" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Color Doppler myocardial imaging: a new technique for the assessment of myocardial function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9440065" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Doppler energy: a new acquisition technique for the transthoracic detection of myocardial perfusion defects with the use of a venous contrast agent.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8935502" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Combining pulse compression and adaptive drive signal design to inverse filter the transducer system response and improve resolution in medical ultrasound.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9577478" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Prolongation and optimization of Doppler enhancement with a microbubble US contrast agent by using continuous infusion: preliminary experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10689253" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Infusion versus bolus contrast echocardiography: a multicenter, open-label, crossover trial.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
